Schistosoma Haematobium Infections and Praziquantel

Phase 3

Completed

• Conditions: Schistosomiasis
• Interventions: Drug: praziquantel

• Registration Number: NCT01558336
• Lead Sponsor: University of Khartoum

Brief Summary

The purpose of this study is to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan.

Detailed Description

A longitudinal study will be conducted to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan. A cohort of schoolchildren (6-15 years of age) was investigated before and 1 year after treatment with a single dose of praziquantel 40mg/kg.

Study Timeline

• Study Start: 2008-08
• Study First Submitted: 2012-03-16
• Study First Submitted QC: 2012-03-19
• Study First Posted: 2012-03-20
• Primary Completion: 2012-08
• Study Completion: 2012-09
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-16
• Last Update Posted: 2013-01-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 520

Inclusion Criteria

• School children

Exclusion Criteria

• Taking praziquantel

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Praziguantel	praziquantel	tablet single dose

Primary Outcome Measures

Name	Time	Method
cure rate	one year	The reduction of the prevalence and intensity of S.haematobium infection following a single dose of praziquantel40mg/kg

Secondary Outcome Measures

Name	Time	Method
reduction in the intensity of infection by	one year	will a single dose of PZQ significantly reduced intensity of infection of S. haematobium infection 1 year after treatment

Trial Locations

Locations (1)

Al Salamania; 🇸🇩 Al Salamania, Nile, Sudan